Lannett Co Inc (LCI): Price and Financial Metrics


Lannett Co Inc (LCI)

Today's Latest Price: $7.01 USD

0.03 (-0.43%)

Updated Oct 23 7:00pm

Add LCI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LCI Stock Summary

  • The price/operating cash flow metric for Lannett Co Inc is higher than only 14.77% of stocks in our set with a positive cash flow.
  • Over the past twelve months, LCI has reported earnings growth of -106.96%, putting it ahead of only 17.34% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for LCI comes in at 23.03% -- higher than that of 89.31% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lannett Co Inc are HL, FCEL, SPR, ENVA, and CETX.
  • LCI's SEC filings can be seen here. And to visit Lannett Co Inc's official web site, go to www.lannett.com.

LCI Stock Price Chart Interactive Chart >

Price chart for LCI

LCI Price/Volume Stats

Current price $7.01 52-week high $13.12
Prev. close $7.04 52-week low $4.89
Day low $6.90 Volume 173,668
Day high $7.08 Avg. volume 636,632
50-day MA $6.11 Dividend yield N/A
200-day MA $7.27 Market Cap 281.95M

Lannett Co Inc (LCI) Company Bio


Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

LCI Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$7.01$10.67 52%

We started the process of determining a valid price forecast for Lannett Co Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lannett Co Inc ranked in the 56th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 53%. The most interesting components of our discounted cash flow analysis for Lannett Co Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 0.27 -- which is good for besting only 24.78% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • 28% of the company's capital comes from equity, which is greater than merely 11.93% of stocks in our cash flow based forecasting set.
  • Lannett Co Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%49%
1%51%
2%52%
3%54%
4%55%
5%57%

Want more companies with a valuation profile/forecast similar to that of Lannett Co Inc? See UNH, ACIU, REGN, EGRX, and UTHR.


LCI Latest News Stream


Event/Time News Detail
Loading, please wait...

LCI Latest Social Stream


Loading social stream, please wait...

View Full LCI Social Stream

Latest LCI News From Around the Web

Below are the latest news stories about Lannett Co Inc that investors may wish to consider to help them evaluate LCI as an investment opportunity.

Lannett: Using SWOT Analysis To Assess The Company

If we have learned anything from the COVID-19 pandemic of 2020 it is the past is not a predictor of the future and that the only certainty is uncertainty. Yet, for businesses, the effort to forecast the future remains a much sought-after goal and often pursued through data from the...

StrategyDoc on Seeking Alpha | September 4, 2020

Lannett: Poor, Near-Term Prospect And Less Impressive, Long-Term Opportunities Than Initially Thought, Avoid This Stock

Investment Thesis We have been bullish on Lannett (LCI) because of its achievement the last 12 months in filling the $200M void that Levo had created, and also its roadmap to $1B in revenue by 2025. Today, the company hits a roadblock. The gap remains large as competitive pressure has...

DTF Capital on Seeking Alpha | August 31, 2020

Analysis on Impact of COVID-19 - Global Legal Cocaine Market 2020-2024 | Evolving Opportunities with Bio-Techne Corp. and Lannett Co. Inc. | Technavio

LONDON--(BUSINESS WIRE)-- #GlobalLegalCocaineMarket--The Global Legal Cocaine Market will grow by 1.27 th oz during 2020-2024

Business Wire | August 27, 2020

Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus®

/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically…

PR Newswire | August 17, 2020

Lannett Launches Mexiletine HCl Capsules

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the AB-rated generic equivalent to Mexitil® Capsules of Boehringer Ingelheim.

Yahoo | July 23, 2020

Read More 'LCI' Stories Here

LCI Price Returns

1-mo 20.45%
3-mo 24.07%
6-mo -23.97%
1-year -40.94%
3-year -70.36%
5-year -83.77%
YTD -20.52%
2019 77.82%
2018 -78.62%
2017 5.22%
2016 -45.04%
2015 -6.44%

Continue Researching LCI

Want to see what other sources are saying about Lannett Co Inc's financials and stock price? Try the links below:

Lannett Co Inc (LCI) Stock Price | Nasdaq
Lannett Co Inc (LCI) Stock Quote, History and News - Yahoo Finance
Lannett Co Inc (LCI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8626 seconds.